ES2388963B1 - Desarrollo y uso de nanoparticulas lipidicas conteniendo edelfosina y otros eteres de fosfolipidos en la terapia antitumoral y antiparasitaria - Google Patents

Desarrollo y uso de nanoparticulas lipidicas conteniendo edelfosina y otros eteres de fosfolipidos en la terapia antitumoral y antiparasitaria

Info

Publication number
ES2388963B1
ES2388963B1 ES201130433A ES201130433A ES2388963B1 ES 2388963 B1 ES2388963 B1 ES 2388963B1 ES 201130433 A ES201130433 A ES 201130433A ES 201130433 A ES201130433 A ES 201130433A ES 2388963 B1 ES2388963 B1 ES 2388963B1
Authority
ES
Spain
Prior art keywords
edelphosine
antiparasitary
antitumoral
phospholipids
ethers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201130433A
Other languages
English (en)
Other versions
ES2388963A1 (es
Inventor
Maria J Blanco-Prieto
De Mendoza Ander Estella Hermoso
Martinez Miguel Angel Campanero
Pulgarin Janny Alexander Villa
Miranda Ruben Eduardo Varela
Garcia Faustino Mollinedo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apointech S L
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Navarra
Original Assignee
Apointech S L
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Navarra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apointech S L, Consejo Superior de Investigaciones Cientificas CSIC, Universidad de Navarra filed Critical Apointech S L
Priority to ES201130433A priority Critical patent/ES2388963B1/es
Publication of ES2388963A1 publication Critical patent/ES2388963A1/es
Application granted granted Critical
Publication of ES2388963B1 publication Critical patent/ES2388963B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/08Ethers or acetals acyclic, e.g. paraformaldehyde
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES201130433A 2011-03-24 2011-03-24 Desarrollo y uso de nanoparticulas lipidicas conteniendo edelfosina y otros eteres de fosfolipidos en la terapia antitumoral y antiparasitaria Expired - Fee Related ES2388963B1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES201130433A ES2388963B1 (es) 2011-03-24 2011-03-24 Desarrollo y uso de nanoparticulas lipidicas conteniendo edelfosina y otros eteres de fosfolipidos en la terapia antitumoral y antiparasitaria

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201130433A ES2388963B1 (es) 2011-03-24 2011-03-24 Desarrollo y uso de nanoparticulas lipidicas conteniendo edelfosina y otros eteres de fosfolipidos en la terapia antitumoral y antiparasitaria

Publications (2)

Publication Number Publication Date
ES2388963A1 ES2388963A1 (es) 2012-10-22
ES2388963B1 true ES2388963B1 (es) 2013-09-13

Family

ID=46940874

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201130433A Expired - Fee Related ES2388963B1 (es) 2011-03-24 2011-03-24 Desarrollo y uso de nanoparticulas lipidicas conteniendo edelfosina y otros eteres de fosfolipidos en la terapia antitumoral y antiparasitaria

Country Status (1)

Country Link
ES (1) ES2388963B1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586621B2 (en) * 2006-10-27 2013-11-19 Michael A. Zeligs Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
CA2746129A1 (en) * 2008-12-11 2010-06-17 Abraxis Bioscience, Llc Combination chemotherapy of nanoparticulate taxanes and inhibitors of pro-survival and/or inflammatory signals

Also Published As

Publication number Publication date
ES2388963A1 (es) 2012-10-22

Similar Documents

Publication Publication Date Title
IL280771A (en) Lipid nanoparticle compositions and methods for mrna delivery
IL280819A (en) Adeno-associated virus virions with variant capsid and methods of use thereof
EP2701686A4 (en) LIPID BINCHES SUPPORTED ON POROUS NANOPARTICLES (PROTOCELLS) FOR TARGETED ADMINISTRATION, AND METHODS OF USE THEREOF
EP3010528A4 (en) In vivo targeting of cells with ligand-conjugated particles
HRP20190080T1 (hr) Postupak i formulacija za inhaliranje
SI3552619T1 (sl) Polipeptidi faktorja IX in načini njihove uporabe
EP3088353B8 (en) Bilirubin particles and their preparation for use in therapy
EP2861072A4 (en) NATURAL COMBINED HORMONRY SUB-FORMULATIONS AND THERAPIES
IL226377A0 (en) Nanoparticle isoflavone compositions & methods of making and using the same
SMT201400146B (it) Morfolino pirimidine e loro uso in terapia
SI3067358T1 (sl) Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba
EP3046547A4 (en) Core and surface modification of mesoporous silica nanoparticles to achieve cell specific targeting in vivo
CO6870033A2 (es) Compuestos terapéuticos y métodos de uso relacionados
EP2668212A2 (en) Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
DK2834348T3 (da) 3d in vitro bifasisk brusk-knogle-konstruktion
PL2780036T3 (pl) Kompozycje nanocząstek do generowania regulatorowych komórek t i leczenie chorób autoimmunologicznych i innych przewlekłych stanów zapalnych
IL231222B (en) Preparations containing oxidized phospholipids
IL248319A0 (en) Methods of delivering weight loss therapy to patients with major depression
BR112012029412A2 (pt) partículas funcionalizadas e uso destas
BR112013030644A2 (pt) fosfolipídios contendo ácido(s) nitrocarboxílico(s) da estrutura geral (i), e uso dos mesmos, dispositivo médico e composições biopassivadoras
IL236791A0 (en) Compositions and methods for producing the compositions for use in colon emptying
EP2670857A4 (en) 3D CELL DEVELOPMENT ABILITY ANALYSIS
IL229748A0 (en) Compounds that bind to human β1-adrenoceptor (ß1-ar) and their use in the measurement of ar-a1 autoantibodies
PT2590509T (pt) Método para a preparação e utilização de biocidas enriquecidos em radicais ativos antes da utilização
BR112015033065A8 (pt) nanopartícula de lipídio; composição farmacêutica; e uso da nanopartícula de lipídio

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2388963

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20130913

FD2A Announcement of lapse in spain

Effective date: 20181015